New and recently funded Medical Startups
1
Country: USA | Funding: $125.4M
Calyxo has developed the CVAC surgical system for kidney stone removal and the corresponding procedure called SURE. The company's device utilizes irrigation and vacuum aspiration during and after laser lithotripsy to extract stones from patients' kidneys, allowing physicians to completely remove stone fragments. Independent irrigation and aspiration channels ensure continuous flow. Four angled nozzles liquefy fragments for effective removal. Dynamic aspiration removes dust during lithotripsy and removes fragments after lithotripsy. The CVAC system demonstrated safety and superior stone removal in the landmark ASPIRE study.
Calyxo has developed the CVAC surgical system for kidney stone removal and the corresponding procedure called SURE. The company's device utilizes irrigation and vacuum aspiration during and after laser lithotripsy to extract stones from patients' kidneys, allowing physicians to completely remove stone fragments. Independent irrigation and aspiration channels ensure continuous flow. Four angled nozzles liquefy fragments for effective removal. Dynamic aspiration removes dust during lithotripsy and removes fragments after lithotripsy. The CVAC system demonstrated safety and superior stone removal in the landmark ASPIRE study.
2
Country: Israel | Funding: $274M
Nanox Medical develops and manufactures radiographic devices enabling lower radiation dose, higher image resolution and high degree of automation. The company has developed secondary fluorescence technology, which offers significant advantages over traditional Coolidge tubes. Its flagship device - miniC - is a multifunctional, battery-operated, miniature C-arm X-ray system. It provides images and video for orthopedic surgeries, pediatric surgeries and clinical diagnostics. Nanox also produces miniDR-85 - a portable X-ray unit powered by a 60V lithium battery. It is used for diagnostic imaging in medical facilities and emergency situations.
Nanox Medical develops and manufactures radiographic devices enabling lower radiation dose, higher image resolution and high degree of automation. The company has developed secondary fluorescence technology, which offers significant advantages over traditional Coolidge tubes. Its flagship device - miniC - is a multifunctional, battery-operated, miniature C-arm X-ray system. It provides images and video for orthopedic surgeries, pediatric surgeries and clinical diagnostics. Nanox also produces miniDR-85 - a portable X-ray unit powered by a 60V lithium battery. It is used for diagnostic imaging in medical facilities and emergency situations.
3
Country: Israel | Funding: $190M
ForSight Robotics created surgical platform designed specifically for ophthalmological (eye) surgeries — a category requiring a great deal of precision.
ForSight Robotics created surgical platform designed specifically for ophthalmological (eye) surgeries — a category requiring a great deal of precision.
4
Country: USA | Funding: $57.8M
Luminai offers an AI platform aimed at helping ease operations within health systems, including moving data between disconnected systems, easing revenue cycle and billing workflows, assisting with prior authorizations and insurance paperwork, and processing claims, forms and eligibility checks.
Luminai offers an AI platform aimed at helping ease operations within health systems, including moving data between disconnected systems, easing revenue cycle and billing workflows, assisting with prior authorizations and insurance paperwork, and processing claims, forms and eligibility checks.
5
Country: USA | Funding: $1.2B
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
6
Country: USA | Funding: $2.4B
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
7
Country: Netherlands | Funding: $1.3B
uniQure has developed an industry-leading AAV gene therapy platform focused on liver and central nervous system diseases. The company's lead candidate, AMT-130, for the treatment of Huntington's disease consists of an AAV5 vector carrying an artificial micro-RNA specifically tailored to silence the huntingtin gene. The therapeutic goal is to inhibit the production of the mutant protein. The company is also developing candidate AMT-191 for Fabry disease (it delivers a GLA transgene to the liver to enhance GLA protein production), AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene (it is a recombinant AAVrh10 vector expressing microRNA designed to suppress SOD1 expression) and HEMGENIX - the world's first FDA-approved gene therapy for hemophilia B.
uniQure has developed an industry-leading AAV gene therapy platform focused on liver and central nervous system diseases. The company's lead candidate, AMT-130, for the treatment of Huntington's disease consists of an AAV5 vector carrying an artificial micro-RNA specifically tailored to silence the huntingtin gene. The therapeutic goal is to inhibit the production of the mutant protein. The company is also developing candidate AMT-191 for Fabry disease (it delivers a GLA transgene to the liver to enhance GLA protein production), AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene (it is a recombinant AAVrh10 vector expressing microRNA designed to suppress SOD1 expression) and HEMGENIX - the world's first FDA-approved gene therapy for hemophilia B.
8
Country: USA | Funding: $89.6M
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. The company has built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. Its initial focus is on immunology and cardiometabolic indications.
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. The company has built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. Its initial focus is on immunology and cardiometabolic indications.
9
Country: USA | Funding: $141M
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
10
Country: USA | Funding: $459.7M
Synthego is a provider of synthetic RNA solutions for CRISPR Genome Engineering.
Synthego is a provider of synthetic RNA solutions for CRISPR Genome Engineering.
